Authors' objectives: The present assessment addressed the research question whether the lithium triborate (LBO) laser for photoselective vaporisation of the prostate (PVP) in the treatment of benign prostatic hyperplasia (BPH) was more effective and/or safer than its comparators. The technology has been identified as the GreenLight XPS for which the manufacturer, Boston Scientific, claims advantages in terms of shorter hospital stay (because the procedure can be done as a day-case procedure); shorter duration of catheterisation; quicker return to normal activity following treatment; reduction in pain leading to improved quality of life; can be used for patients taking anticoagulants and those with larger prostates; reduction in hospital readmissions; reduced risk of capsular perforation, bleeding and TURP syndrome.

Project Status: Completed

URL for protocol: https://eunethta.eu/otca17-final-assessment-report-and-related-documents-now-available/

Year Published: 2019

URL for published report: https://eunethta.eu/otca17-final-assessment-report-and-related-documents-now-available/

Requestor: HTA agencies

English language abstract: An English language summary is available

Publication Type: Rapid Review

Organisation Name: European Network for Health Technology Assessment

Contact Email: eunethta@zinl.nl

Copyright: CC-BY-NC: You may copy, distribute, display, perform, and modify and use the EUnetHTA work for any purpose other than commercially unless you get your permission first.